Journal article
Pemetrexed Induced Life-threatening Anaphylaxis
Curēus (Palo Alto, CA), Vol.11(8), e5514
08/29/2019
DOI: 10.7759/cureus.5514
PMCID: PMC6818736
PMID: 31687290
Abstract
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death. The American Society for Clinical Oncology (ASCO) recommends platinum based regimens as the first-line of treatment for NSCLC. Pemetrexed, an antifolate agent, has been approved by the ASCO for the treatment of advanced non-squamous NSCLC and has been shown to be efficient for first-line, maintenance and second- or third-line treatment in this subgroup. It is administered intravenously over 10 minutes and is usually well tolerated with a very few side effects. There have been a few cases of anaphylaxis reported with pemetrexed use and most of the patients presented only with cutaneous manifestations. We present a patient with stage IV adenocarcinoma of the lung who developed a severe life threatening anaphylactic reaction requiring ventilatory support after administration of pemetrexed.
Details
- Title: Subtitle
- Pemetrexed Induced Life-threatening Anaphylaxis
- Creators
- Venkat Rajasurya - Novant HealthBimatshu Pyakuryal - Nepal Medical College Teaching HospitalKulothungan Gunasekaran - Bridgeport HospitalVijaykumar Sekar - Bassett Medical CenterPrajwal Dhakal - University of Nebraska Medical Center
- Resource Type
- Journal article
- Publication Details
- Curēus (Palo Alto, CA), Vol.11(8), e5514
- DOI
- 10.7759/cureus.5514
- PMID
- 31687290
- PMCID
- PMC6818736
- NLM abbreviation
- Cureus
- ISSN
- 2168-8184
- eISSN
- 2168-8184
- Publisher
- Cureus Inc
- Number of pages
- 4
- Language
- English
- Date published
- 08/29/2019
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984361562702771
Metrics
3 Record Views